Abstract
The pharmacokinetics of cefmenoxime were determined after a 30-min intravenous infusion of 15 mg/kg of total body weight to 33 adult subjects with normal renal function (CLCR, greater than 80 ml/min per 1.73 m2, group I), mild renal insufficiency (CLCR, 40 to 79 ml/min per 1.73 m2, group II), moderate renal insufficiency (CLCR, 10 to 39 ml/min per 1.73 m2, group III), or severe renal impairment, (CLCR, less than 10 ml/min per 1.73 m2, group IV) or to patients between hemodialysis (CLCR, less than 10 ml/min per 1.73 m2, group V). Concentrations of cefmenoxime in serum and urine were determined by high-pressure liquid chromatography, and serum concentrations were fit to a two-compartment model. There was no significant relationship between creatinine clearance and either peak serum concentrations or volume of distribution at steady state. Patients in group I excreted 81% of the dose into the urine within 24 h; recovery decreased with worsening renal function. The mean terminal half-lives in groups I to V were 1.06, 1.50, 3.55, 4.60, and 11.4 h, respectively. There were good linear relationships between creatinine clearance, and the elimination rate and total body clearance of cefmenoxime. Dosage recommendations for subjects with renal insufficiency are proposed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Granneman G. R., Sennello L. T., Steinberg F. J., Sonders R. C. Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects. Antimicrob Agents Chemother. 1982 Jan;21(1):141–145. doi: 10.1128/aac.21.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Höffler D., Koeppe P. Pharmacokinetics of Cefmenoxime in normal and impaired renal function. Arzneimittelforschung. 1983;33(2):269–272. [PubMed] [Google Scholar]
- Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
- Noonan I. A., Gambertoglio J. G., Barriere S. L., Conte J. E., Jr, Lin E. T. High-performance liquid chromatographic determination of cefmenoxime (AB-50912) in human plasma and urine. J Chromatogr. 1983 Apr 8;273(2):458–463. doi: 10.1016/s0378-4347(00)80971-8. [DOI] [PubMed] [Google Scholar]
- Quintiliani R. Bleeding disorders associated with newer cephalosporins. Clin Pharm. 1983 Jul-Aug;2(4):360–361. [PubMed] [Google Scholar]
- Sennello L. T., Quinn D., Rollins D. E., Tolman K. G., Sonders R. C. Effect of probenecid on the pharmacokinetics of cefmenoxime. Antimicrob Agents Chemother. 1983 Jun;23(6):803–807. doi: 10.1128/aac.23.6.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith B. R., LeFrock J., Carr B. B. Cefmenoxime penetration into gallbladder bile and tissue. Antimicrob Agents Chemother. 1983 Jun;23(6):941–943. doi: 10.1128/aac.23.6.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith C. R., Lipsky J. J. Hypoprothrombinemia and platelet dysfunction caused by cephalosporin and oxalactam antibiotics. J Antimicrob Chemother. 1983 Jun;11(6):496–499. doi: 10.1093/jac/11.6.496. [DOI] [PubMed] [Google Scholar]
- Stamm J. M., Girolami R. L., Shipkowitz N. L., Bower R. R. Antimicrobial activity of cefmenoxime (SCE-1365). Antimicrob Agents Chemother. 1981 Mar;19(3):454–460. doi: 10.1128/aac.19.3.454. [DOI] [PMC free article] [PubMed] [Google Scholar]